References
White WB, Hanes V, Chauhan V, Pitt B: Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006, 48:246–253.
Archer DF, Thorneycroft IH, Foegh M, et al.: Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005, 12:716–727.
Preston RA, White WB, Pitt B, et al.: Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005, 18:797–804.
Preston RA, Alonso A, Panzitta D, et al.: Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002, 15:816–822.
Schurmann R, Blode H, Benda N, et al.: Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006, 46:867–875.
Rights and permissions
About this article
Cite this article
Berecek, K.H., Nielsen, T.D. Antihypertensive ffects of drospirenone and 17α-estradiol in hypertensive postmenopausal women. Current Science Inc 9, 209–210 (2007). https://doi.org/10.1007/s11906-007-0037-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-007-0037-z